ClinicalTrials.gov
public full text
Public Domain
A Phase I Trial of HS-10241 in Solid Tumors
This is a phase 1, open-label, dose-escalation trial of HS-10241 as monotherapy in subjects with solid tumors. HS-10241 will be administered orally once daily.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors#1150096
- A Phase I Study of G3139 Subcutaneous in Solid Tumors#859594
- Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors#1058413
- A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors#800662
- A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma#887177
Record · ID 969928
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive